



## PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
<b>TITLE</b>			
Title	1	Identify the report as a systematic review.	1
<b>ABSTRACT</b>			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	4
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	4
<b>METHODS</b>			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	5
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	6
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	6
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	6-7
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	7
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	5-6
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	5-6
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	7
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	7-8
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	7-8
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	-
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	-
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	7-8
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	7-8
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	-
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	-
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	-



## PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
<b>RESULTS</b>			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	8
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	8
Study characteristics	17	Cite each included study and present its characteristics.	8
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	11
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	8
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	9-10
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	9-10
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	9-10
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	-
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	-
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	-
<b>DISCUSSION</b>			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	11-14
	23b	Discuss any limitations of the evidence included in the review.	15
	23c	Discuss any limitations of the review processes used.	15
	23d	Discuss implications of the results for practice, policy, and future research.	16
<b>OTHER INFORMATION</b>			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	5
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	5
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	5
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	17
Competing interests	26	Declare any competing interests of review authors.	17
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	17

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>

PubMed: 559 results

**("vasopressor\*" OR epinephrine[MeSH Terms] OR norepinephrine[MeSH Terms] OR phenylephrine[MeSH Terms] OR vasopressins[MeSH Terms] OR Dopamine[MeSH Terms] OR angiotensins[MeSH Terms]) AND (covid-19) Filters: English**

Scopus: 401 results

TITLE-

ABS ( "vasopressor\*" OR "epinephrine" OR "norepinephrine" OR "phenylephrine" OR "vasopressin\*" OR "dopamine" OR "angiotensin" ) AND TITLE-ABS-KEY ( "COVID-19" ) AND TITLE-ABS-KEY ( "critically ill" OR icu OR "intensive care" ) AND ( EXCLUDE ( SRCTYPE , "k" ) OR EXCLUDE ( SRCTYPE , "p" ) ) AND ( EXCLUDE ( DOCTYPE , "re" ) OR EXCLUDE ( DOCTYPE , "le" ) OR EXCLUDE ( DOCTYPE , "ed" ) OR EXCLUDE ( DOCTYPE , "no" ) OR EXCLUDE ( DOCTYPE , "sh" ) OR EXCLUDE ( DOCTYPE , "cp" ) OR EXCLUDE ( DOCTYPE , "ch" ) OR EXCLUDE ( DOCTYPE , "tb" ) ) AND ( EXCLUDE ( LANGUAGE , "French" ) OR EXCLUDE ( LANGUAGE , "Russian" ) OR EXCLUDE ( LANGUAGE , "Spanish" ) OR EXCLUDE ( LANGUAGE , "Chinese" ) OR EXCLUDE ( LANGUAGE , "Persian" ) OR EXCLUDE ( LANGUAGE , "Portuguese" ) OR EXCLUDE ( LANGUAGE , "German" ) OR EXCLUDE ( LANGUAGE , "Hungarian" ) )

Clinicaltrials.gov: 15 results

**Completed Studies | (vasopressor OR epinephrine OR norepinephrine OR phenylephrine OR vasopressin OR Dopamine OR angiotensin) AND (covid-19)**

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O
1	A/A	Author	Mortality Definition	AKI Definition											
2		1 Ionescu	In-hospital mortality	NA											
3		2 Pelayo	In-hospital mortality	Kidney Disease: Improving Global Outcomes (KDIGO) guidelines											
4		3 Lowe	In-hospital mortality	Kidney Disease: Improving Global Outcomes (KDIGO) guidelines											
5		4 Hansrivijit	In-hospital mortality	Kidney Disease: Improving Global Outcomes (KDIGO) guidelines											
6		5 Mesquida	NA	NA											
7		6 Ghosn	In-hospital mortality	Data only for patients with Stage 2 and Stage 3 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines											
8		7 Farooqui	30-day mortality	NA											
9		8 de Menezes Neves	30-day mortality	Kidney Disease: Improving Global Outcomes (KDIGO) guidelines											
10		9 Bernardo	NA	Kidney Disease: Improving Global Outcomes (KDIGO) guidelines											
11		10 Hardenberg	In-hospital mortality	Data only for patients with Stage 3 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines											
12		11 Geri	28-day mortality	Kidney Disease: Improving Global Outcomes (KDIGO) guidelines											
13		12 Namendys-Silva	In-hospital mortality	NA											
14		13 Auld	ICU mortality	NA											
15		14 Nabors	In-hospital mortality	NA											
16		15 Salacup	In-hospital mortality	NA											
17		16 Nasrulah	In-hospital mortality	NA											
18		17 Sjostrom	90-day mortality	NA											
19		18 Ismail	In-hospital mortality	NA											
20		19 Osofu-Barko	NA	NA											
21		20 Ramkumar	NA	NA											
22		21 ACCCOS	30-day mortality	NA											
23		22 Mamen	NA	NA											
24		23 Andrade	In-hospital mortality	Kidney Disease: Improving Global Outcomes (KDIGO) guidelines											
25		24 Chand	30-day mortality	Kidney Disease: Improving Global Outcomes (KDIGO) guidelines											
26		25 Bezzera	In-hospital mortality	Kidney Disease: Improving Global Outcomes (KDIGO) guidelines											
27		26 Gundogan	90-day mortality	Kidney Disease: Improving Global Outcomes (KDIGO) guidelines											
28		27 Dang	In-hospital mortality	NA											
29		28 Estella	6-week mortality	NA											
30		29 Gadhya	In-hospital mortality	Kidney Disease: Improving Global Outcomes (KDIGO) guidelines											
31		30 Brandao Neto	In-hospital mortality	NA											
32		31 Burrell	ICU mortality	NA											
33		32 Zangrillo	one-week after angiotensin administration	NA											
34		33 Leisman	In-hospital mortality	NA											
35		34 Neto	ICU mortality and in-hospital mortality	NA											
36															
37															
38															

	A	B	C	D	E	F	G	H	I
1	Author	Mortality					Adverse events (EVENTS/Patients)		
2		Comment	Vasopressors		Placebo-No vasopressors		Type of event	Intervention (Events/N of patients)	Placebo-No vasopressors (Events/N of patients)
3			Deaths	N of patients	Deaths	N of patients			
4	Osofu-Barko	-	4	10	NA		-	-	-
5	Leisman	-	4	10	10	19	Thrombotic events	0/10	3/19
6							Secondary infection	3/10	7/19
7	Neto	ICU mortality	33	65	24	67	AKI	50/65	44/64
8		In-hospital mortality	35	65	27	67			
9									
10									

	J	K	L	M	N	O	P	Q
1	Vasopressor free days Mean ± SD / Median (IQR)		Ventilator free days Mean ± SD / Median (IQR)		Baseline hemodynamic profile Mean ± SD / Median (IQR)			
2	Intervention	Placebo-No vasopressors	Intervention	Placebo-No vasopressors	HR (bpm)	MAP (mmHg)	Urinary output (ml/hr)	Lactate (mmol/L)
3					Vasopressors/No vasopressors	Vasopressors/No vasopressors	Vasopressors/No vasopressors	Vasopressors/No vasopressors
4	-	-	-	-	-	Mean: 75	Mean: 10	-
5	2.8 ± 2.49	3.9 ± 2.5	0.3 ± 0.7	0.1 ± 0.5	-	69.2 (60-81)/83.2 (68-95)	-	-
6								
7	-	-	0 (0-15)	1 (0-15)	102 (81-118)/98 (86-102)	80 (69-94)/73 (63-89)	-	1.7 (1.4-2.2)/1.9 (1.2-2.5)
8								
9								
10								

Q	R	S	T	U	V
	Post-resuscitation hemodynamic profile Mean $\pm$ SD / Median (IQR)				
Lactate (mmol/L)	Timepoints	HR (bpm)	MAP (mmHg)	Urinary output (ml/hr)	Lactate (mmol/L)
Vasopressors/No vasopressors		Vasopressors/No vasopressors	Vasopressors/No vasopressors	Vasopressors/No vasopressors	Vasopressors/No vasopressors
-	6 hours after angiotensin administration		Mean: 85	Mean: 45	
-	6 hours after angiotensin administration	-	80 (NA) / NA	-	-
7 (1.4-2.2)/1.9 (1.2-2.5)	6 hours after angiotensin administration	95 (77-104)/94 (81-111)	76 (65-87)/79 (69-86)	-	1.6 (1.2-2.4)/1.8 (1.2-2.4)
	12 hours after angiotensin administration	79 (72-81)/70 (69-87)	79 (72-81)/70 (69-87)		1.4 (1.2-2.1)/1.5 (1.3-2.1)


	A	B	C	D	E	F	G	H	I	J	K	L	M
1		Study	ACCOS	Andrade	Auld	Bernardo	Bezzera	Brandao Neto	Burrell	Chand	Dang	Menezes New	Estella
2		1	2	2	1	2	2	2	2	1	2	2	2
3		2	1	2	2	2	2	2	2	2	2	2	1
4		3	2	0	0	0	0	2	2	0	0	0	2
5		4	2	2	1	2	2	2	2	2	2	2	2
6		5	0	0	0	0	0	0	0	0	0	0	0
7		6	2	2	1	2	2	2	2	2	2	2	2
8	Question/Parameter	7	2	2	2	2	2	2	2	2	2	2	2
9		8	0	0	0	0	0	0	0	0	0	0	0
10			Additional criteria for comparative studies										
11		9	2	2	2	2	2	2	2	2	2	2	2
12		10	2	2	2	2	2	2	2	2	2	2	2
13		11	0	0	0	0	0	0	0	0	0	0	0
14		12	2	2	2	1	2	2	2	2	2	2	2
15		Total	17	16	13	15	16	18	18	15	16	16	17
16													
17													
18													
19													
20													
21													
22													
23													
24													
25													



	A	B	N	O	P	Q	R	S	T	U	V	W	X	Y
1		Study	Farooqui	Gadhiya	Geri	Ghosn	Hansrivijit	Hardenberg	Ionescu	Ismail	Leisman	Lowe	Nabors	Nasrulah
2		1	1	2	2	2	2	2	2	2	2	2	2	2
3		2	2	2	2	2	2	2	2	2	2	2	2	2
4		3	0	0	0	0	0	0	0	0	0	0	0	0
5		4	2	2	2	2	2	2	2	2	2	1	1	2
6		5	0	0	0	0	0	0	0	0	0	0	0	0
7		6	2	2	2	2	2	2	2	2	2	2	2	2
8	Question/Parameter	7	2	2	2	2	2	2	2	2	2	2	2	2
9		8	0	0	0	0	0	0	0	0	0	0	0	0
10														
11		9	2	2	2	2	2	2	2	2	2	2	2	2
12		10	2	2	2	2	2	2	2	2	2	2	2	2
13		11	0	0	0	0	0	0	0	0	2	0	0	0
14		12	2	2	2	2	2	2	2	2	2	2	2	2
15		Total	15	16	16	16	16	16	16	16	18	15	15	16
16														
17														
18														
19														
20														
21														
22														
23														
24														
25														

	A	B	Z	AA	AB	AC	AD	AE	AF	AG
1		Study	Neto	Osofu-Barko	Pelayo	Ramkumar	Salacup	Namendys-Silv	Sjostorm	Mammen
2		1	2	2	2	2	2	2	2	2
3		2	2	2	2	2	2	2	2	2
4		3	2	0	0	2	0	0	2	0
5		4	2	1	1	2	2	2	2	2
6		5	0	0	0	0	0	0	0	0
7		6	2	2	2	2	2	2	2	2
8	Question/Parameter	7	2	2	2	2	2	2	2	2
9		8	0	0	0	0	0	0	0	0
10										
11		9	2	NA	2	2	2	2	2	2
12		10	2	NA	2	2	2	2	2	2
13		11	2	NA	0	0	0	0	0	0
14		12	2	NA	2	2	2	2	2	2
15		Total	20	9	15	18	16	16	18	16
16										
17										
18										
19										
20										
21										
22										
23										
24										
25										

## Appendix D1



## Appendix D2

